
ADMA Biologics Inc (NASDAQ:ADMA - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for ADMA Biologics in a report issued on Thursday, August 7th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of $0.55 for the year, down from their previous forecast of $0.61. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share. Cantor Fitzgerald also issued estimates for ADMA Biologics' FY2026 earnings at $0.80 EPS.
ADMA has been the subject of a number of other research reports. Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.
Read Our Latest Stock Analysis on ADMA
ADMA Biologics Price Performance
ADMA Biologics stock traded down $0.23 during mid-day trading on Friday, hitting $16.52. The company's stock had a trading volume of 4,194,232 shares, compared to its average volume of 3,135,262. The stock has a market capitalization of $3.94 billion, a P/E ratio of 19.21 and a beta of 0.38. ADMA Biologics has a twelve month low of $13.50 and a twelve month high of $25.67. The stock's fifty day moving average price is $18.63 and its two-hundred day moving average price is $18.83. The company has a quick ratio of 3.36, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter last year, the firm posted $0.13 EPS. The business's revenue for the quarter was up 13.8% on a year-over-year basis.
Insider Activity at ADMA Biologics
In other news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,621 shares of company stock valued at $9,644,269. Corporate insiders own 3.50% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of ADMA. Amalgamated Bank increased its holdings in ADMA Biologics by 0.8% in the second quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company's stock worth $1,232,000 after buying an additional 540 shares during the last quarter. New York State Teachers Retirement System grew its position in ADMA Biologics by 0.3% in the second quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company's stock worth $4,051,000 after acquiring an additional 571 shares in the last quarter. Cetera Investment Advisers grew its position in ADMA Biologics by 1.3% in the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after acquiring an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ADMA Biologics by 1.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after purchasing an additional 711 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in shares of ADMA Biologics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after purchasing an additional 746 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.